|
|
|
Company Name
|
ISIS Pharmaceuticals Inc
|
|
Drug Name
|
mipomersen injection, also known as Kynamro (NDA)
|
|
Event Name
|
FDA panel to review Kynamro for homozygous familial hypercholesterolemia
|
|
Event Date
|
10/18/2012
|
|
Outcome
|
FDA panel backs Kynamro for homozygous familial hypercholesterolemia
|
|
Drug Status
|
Isis licensed mipomersen to Genzyme in 2008, which is now a unit of French pharmaceutical giant Sanofi
|
|
Rival Drugs
|
|
|
Market Potential
|
|
|
Other Approvals
|
|
|
News |
|
|
|
Return to FDA Calendar
|